Centers | ||
|
|
|
EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) | Edinburgh Drug Discovery |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all Takeda Partners with Florida Hospital & Sanford-Burnham in Obesity AreaTakeda Pharmaceuticals has entered into a collaboration with Florida Hospital and Sanford-Burnham Medical Institute to discover and develop new therapeutic approaches to treat obesity. The two collaboration agreement will involve Takeda providing... View all |
No EVENTS for listing |
No Job Posts |
